8-K: Polomar Health Services to Restate Financials Following SEC Comment on Polomar Specialty Pharmacy Acquisition

Polomar Health Services will restate its financial statements for the period ended September 30, 2024, due to an SEC comment regarding the accounting treatment of its acquisition of Polomar Specialty Pharmacy.

Summary

• Polomar Health Services, Inc. will restate its financial statements for the three and nine months ended September 30, 2024.
• This decision follows a comment letter from the SEC regarding the accounting treatment of the acquisition of Polomar Specialty Pharmacy, LLC.
• The company initially treated the acquisition as a reverse merger, but now considers it a recapitalization.
• The reclassification will materially impact previously reported balance sheets and statements of stockholders' deficit.
• The company advises investors not to rely on the previously issued financial statements for the specified period.
• The restatement will not affect the company's net loss, stockholders' equity, basic or diluted earnings per share, cash flow, or non-GAAP financial measures.
• The company plans to file an amendment to the original Form 10-Q to correct the errors.
• The company's management has discussed these matters with its independent registered public accounting firm, GreenGrowth CPA LLP.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to the need for a financial restatement, indicating a prior accounting error. However, the impact is somewhat mitigated by the fact that key financial metrics like net loss and cash flow are not affected.

Positives

• The restatement will not affect the company's net loss, stockholders' equity, basic or diluted earnings per share, cash flow, or non-GAAP financial measures.
• The company is taking prompt action to correct the errors by filing an amendment to the original Form 10-Q.

Negatives

• The company's previously issued financial statements for the three and nine months ended September 30, 2024, should no longer be relied upon.
• The reclassification from business combination to recapitalization is expected to materially impact the company's previously reported balance sheets and statements of stockholders deficit.

Risks

• The company's actual results may differ materially from anticipated results due to business, economic, and competitive uncertainties.
• The company's forward-looking statements are subject to assumptions that are subject to change.

Future Outlook

The company plans to amend and restate its financial statements for the three and nine months ended September 30, 2024.

Management Comments

• The company and its management have discussed the matters disclosed in this filing with its independent registered public accounting firm, GreenGrowth CPA LLP.

Industry Context

It's not uncommon for companies to receive comment letters from the SEC and subsequently restate their financials. This situation highlights the importance of accurate accounting practices and compliance with SEC regulations. The impact on investor confidence will depend on the materiality of the restatement and the company's ability to promptly address the issues.

Stakeholder Impact

• Shareholders are advised not to rely on the previously issued financial statements for the specified period.
• The restatement could impact investor confidence in the short term.

Next Steps

• The company will file an amendment to the original Form 10-Q.
• The company will restate its financial statements for the three and nine months ended September 30, 2024.

Key Dates

Keywords

financial restatement, SEC comment, Polomar Health Services, Polomar Specialty Pharmacy, recapitalization, reverse merger, financial statements, accounting